In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Skinvisible expands to India

This article was originally published in The Rose Sheet

Executive Summary

Avani International will distribute Skinvisible's Invisicare technology and products in India, Skinvisible announces. Inviscare - which enhances the delivery of topical dermatology products on skin - was recently granted a comprehensive patent in India, the company says. Under the terms of the agreement, Avani will seek licenses in India for topical products such as hand sanitizers and items that treat acne, fungal infections and atopic dermatitis. The Indian firm also will facilitate clinical studies and manufacturing in the country. "It is important for Skinvisible to develop partnerships with companies such as Avani as they have established relationships with pharmaceutical and consumer goods companies in India. This helps us fast-track our marketing efforts in the country and generate license fees and royalties quicker than marketing in India ourselves," Terry Howlett, president and CEO of Skinvisible, says. The deal is part of Skinvisible's strategy for rapid global expansion



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts